JP2019531352A - ベルベリンナノ粒子を用いた免疫疾患の治療 - Google Patents

ベルベリンナノ粒子を用いた免疫疾患の治療 Download PDF

Info

Publication number
JP2019531352A
JP2019531352A JP2019541688A JP2019541688A JP2019531352A JP 2019531352 A JP2019531352 A JP 2019531352A JP 2019541688 A JP2019541688 A JP 2019541688A JP 2019541688 A JP2019541688 A JP 2019541688A JP 2019531352 A JP2019531352 A JP 2019531352A
Authority
JP
Japan
Prior art keywords
berberine
composition
nanoparticles
administered
heparin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019541688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531352A5 (https=
Inventor
リー，シウ−ミン
リウ，チャンダ
スリヴァタヴァ，カマル
ユ，ハイチョン
エヌ． パーカー，ショーン
エヌ． パーカー，ショーン
Original Assignee
アイカーン スクール オブ メディスン アット マウント シナイ
アイカーン スクール オブ メディスン アット マウント シナイ
ショーン エヌ． パーカー ファウンデーション
ショーン エヌ． パーカー ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイカーン スクール オブ メディスン アット マウント シナイ, アイカーン スクール オブ メディスン アット マウント シナイ, ショーン エヌ． パーカー ファウンデーション, ショーン エヌ． パーカー ファウンデーション filed Critical アイカーン スクール オブ メディスン アット マウント シナイ
Publication of JP2019531352A publication Critical patent/JP2019531352A/ja
Publication of JP2019531352A5 publication Critical patent/JP2019531352A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Composite Materials (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019541688A 2016-10-14 2017-10-16 ベルベリンナノ粒子を用いた免疫疾患の治療 Pending JP2019531352A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408541P 2016-10-14 2016-10-14
US62/408,541 2016-10-14
PCT/US2017/056822 WO2018071917A1 (en) 2016-10-14 2017-10-16 Treatment of immunological disease using berberine nanoparticles

Publications (2)

Publication Number Publication Date
JP2019531352A true JP2019531352A (ja) 2019-10-31
JP2019531352A5 JP2019531352A5 (https=) 2020-11-26

Family

ID=61906052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019541688A Pending JP2019531352A (ja) 2016-10-14 2017-10-16 ベルベリンナノ粒子を用いた免疫疾患の治療

Country Status (7)

Country Link
US (1) US11351157B2 (https=)
EP (1) EP3525760A4 (https=)
JP (1) JP2019531352A (https=)
CN (1) CN110290780A (https=)
AU (1) AU2017342558A1 (https=)
CA (1) CA3039587A1 (https=)
WO (1) WO2018071917A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023506028A (ja) * 2019-12-23 2023-02-14 プロタ セラピューティクス ピーティワイ リミテッド 医薬組成物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182437A1 (en) * 2020-06-11 2021-12-16 Andrei V. Tkatchenko Methods and compositions for preventing and treating myopia with berberine, a berberidaceaen alkaloid, and derivatives thereof
CN114487444B (zh) * 2021-12-28 2024-09-20 上海睿康生物科技有限公司 一种测定血清中抗穆勒氏管激素含量的检测试剂盒
CN114460301B (zh) * 2021-12-28 2024-11-29 上海睿康生物科技有限公司 一种测定血清中肌酸激酶同工酶含量的检测试剂盒
CN114306640A (zh) * 2022-01-27 2022-04-12 南方医科大学南方医院 一种增加小檗碱溶解度的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080254078A1 (en) * 2005-09-16 2008-10-16 Peter Kauper Chitosan-Based Particles
JP2009511549A (ja) * 2005-10-14 2009-03-19 アドバンスド、イン、ビートロウ、セル、テクノロジーズ、ソシエダッド、リミターダ キトサンおよびヘパリンナノ粒子
US20150132399A1 (en) * 2013-10-29 2015-05-14 Shaker A. Mousa Composition and method for sulfated non-anticoagulant low molecular weight heparins in cancer and tumor metastasis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1973608A1 (en) * 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US8802076B2 (en) * 2010-10-04 2014-08-12 Duke University Compositions and methods for modulating an immune response
CN105188741A (zh) * 2013-04-03 2015-12-23 阿勒丁医疗公司 新型纳米颗粒组合物
US20160067241A1 (en) * 2013-06-13 2016-03-10 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
US10500169B2 (en) * 2014-09-17 2019-12-10 Xiu-Min Li Supression of IgE production by compounds derived from traditional chinese medicine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080254078A1 (en) * 2005-09-16 2008-10-16 Peter Kauper Chitosan-Based Particles
JP2009511549A (ja) * 2005-10-14 2009-03-19 アドバンスド、イン、ビートロウ、セル、テクノロジーズ、ソシエダッド、リミターダ キトサンおよびヘパリンナノ粒子
US20150132399A1 (en) * 2013-10-29 2015-05-14 Shaker A. Mousa Composition and method for sulfated non-anticoagulant low molecular weight heparins in cancer and tumor metastasis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ACTA BIOMATERIALIA, vol. 7, JPN6021031530, 2011, pages 593 - 603, ISSN: 0004571456 *
ADVANCED DRUG DELIVERY REVIEWS, vol. 65, JPN6021031524, 2013, pages 865 - 879, ISSN: 0004571459 *
ANNALS OF ALLERGY, ASTHMA AND IMMUNOLOGY, vol. 113, JPN6021031526, 2014, pages 556 - 564, ISSN: 0004571458 *
MARINE DRUGS, vol. 12, JPN6021031532, 2014, pages 5677 - 5697, ISSN: 0004721864 *
NANOMEDICINE, vol. 10, no. 1, JPN6021031528, 2015, pages 57 - 71, ISSN: 0004571457 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023506028A (ja) * 2019-12-23 2023-02-14 プロタ セラピューティクス ピーティワイ リミテッド 医薬組成物

Also Published As

Publication number Publication date
EP3525760A1 (en) 2019-08-21
AU2017342558A1 (en) 2019-05-16
WO2018071917A1 (en) 2018-04-19
US11351157B2 (en) 2022-06-07
CA3039587A1 (en) 2018-04-19
US20200276172A1 (en) 2020-09-03
EP3525760A4 (en) 2020-06-24
CN110290780A (zh) 2019-09-27

Similar Documents

Publication Publication Date Title
JP7368661B2 (ja) 医薬組成物
JP7372897B2 (ja) 改善された粘膜輸送を示す医薬用ナノ粒子
US11351157B2 (en) Treatment of immunological disease using berberine nanoparticles
KR102310775B1 (ko) 개선된 점막 수송을 나타내는 제약 나노입자
CN106061261B (zh) 治疗化合物的结晶形式及其用途
CA2812787A1 (en) Methods for the treatment of allergic diseases
CN1780620A (zh) 含有利鲁唑的局部药物的用途
WO2014141127A1 (en) Composition containing buffered aminoalkyl glucosaminide phosphate derivatives and its use for enhancing an immune response
JP2019038824A (ja) 治療用化合物の結晶形態及びその使用
US20180153984A1 (en) Adjuvant particles comprising adenosine receptor antagonists
US20230346826A1 (en) Compositions and methods for treating and/or preventing autoimmune disorders
Jackson et al. Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization
JP5529377B2 (ja) イヌリンの多形形態およびその使用法
US20240358822A1 (en) Allergy treatment
US9890173B2 (en) Crystalline forms of therapeutic compounds and uses thereof
JP7337389B2 (ja) ヒアルロン酸を有効成分として含むアレルゲン作用増強剤
HK40037930A (en) Pharmaceutical nanoparticles showing improved mucosal transport

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201015

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220308